TXG
10x Genomics, Inc.
September 24, 2026 · market open
- Rarity
- 1.64
- Peak move
- +13.62%
- Float cap
- $8.5B
10x Genomics, Inc. is a life sciences technology company that sells integrated research solutions, including instruments, consumables, and software for analyzing biological systems at single-cell and spatial resolution. Its Chromium, Visium, and Xenium platforms help academic, translational, and biopharmaceutical researchers interrogate oncology, immunology, and neuroscience biology. The company markets to research laboratories and biopharmaceutical companies worldwide.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
5 events · 2 from SEC or newswire · 0 timed with the moveanalyst_ratingDeutsche Bank raised its price target on 10x Genomics (TXG) to $70 from $40 while keeping a Hold rating, as reported September 24, 2026.
insider_saleCEO Serge Saxonov sold 25,000 shares of 10x Genomics on September 22, 2026 at prices from $78.23 to $82.36, for total proceeds of about $2,030,562.
SEC4 0001610717-26-000421insider_sale10x Genomics director Shehnaaz Suliman sold 5,723 Class A shares on September 22, 2026 at prices from $78.20 to $82.28, for total proceeds of about $464,668, following a Form 144 notice and RSU vesting.
institutional_flowARK Investment Management's ARK Genomic Revolution ETF sold 10x Genomics (TXG) shares on September 22, 2026, with reports ranging from roughly 31,600 to 49,651 shares and $2.5 million to $3.93 million in value.
product_launch10x Genomics (TXG) will incorporate Lunit's AI pathology platform Lunit SCOPE IO into its oncology biomarker discovery workflow, pairing whole-slide H&E image analysis with spatial molecular data from the Xenium and Atera platforms.